CSL Seqirus mini oral: Post-ACS Residual CV Risk: What's the Approach to Triglycerides in 2025
| Saturday, August 16, 2025 |
| 3:00 PM - 3:30 PM |
| Theatrette 7 |
Details
"With the recent launch of VAZKEPA® in Australia, triglycerides have re-emerged as a focus as a marker of residual cardiovascular risk among statin-treated patients post-ACS. While statins remain foundational, VAZKEPA® offers a significant advance in therapeutic options to further reduce cardiovascular risk associated with mild-to-moderate hypertriglyceridemia.*1 This session unpacks the evolving science behind triglyceride-rich lipoproteins and explores how PBS-supported access to VAZKEPA®, backed by the REDUCE-IT trial data, is being incorporated into lipid management across clinical practices.1-3 Please join guest speakers Associate Professor Adam Nelson and Professor David Playford to learn more about implementing this therapy for your eligible patients.
*VAZKEPA® is indicated to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk with elevated triglycerides (≥1.7 mmol/L) and established CV disease or diabetes, and at least one other CV risk factor."
Speaker
Assoc Prof Adam Nelson
Interventional Cardiologist
Royal Adelaide and Queen Elizabeth Hospitals / University of Adelaide
Post-ACS Residual CV Risk: What's the Approach to Triglycerides in 2025
3:00 PM - 3:30 PMBiography
Adam Nelson MBBS MBA/MPH PhD FRACP is an early career interventional cardiologist and clinical trialist appointed at the Royal Adelaide and Queen Elizabeth Hospitals, and clinical academic at the University of Adelaide. He is a clinical lead of national and international trials evaluating emerging cardiometabolic therapies and vaccines.
Prof David Playford
Professor of Cardiology
University of Notre Dame Australia
Post-ACS Residual CV Risk: What's the Approach to Triglycerides in 2025
3:00 PM - 3:30 PMBiography
Professor and Head of Cardiology Teaching and Research at the University of Notre Dame, Fremantle, Australia.
Consultant Clinical Cardiologist specializing in Cardiac Imaging and breathlessness assessment.
Regular invited speaker to National and International conferences and many highly cited publications
Founder, Director and Chief Investigator of National Echo Database Australia (NEDA).
Advisor to Echo IQ, an ASX listed company focused on automation and risk detection using echocardiographic data (ASX:EIQ).
